

Pancreatic Cancer (Adenocarcinoma) Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: Neoadjuvant/Pre-Op Adjuvant/Post-Op
 1st Line 2nd Line 3rd Line 3rd Line+

ECOG Performance Status: _____ **ICD-10 Code:** _____

Adjuvant Therapy

Capecitabine (Xeloda) and gemcitabine (Gemzar)

FULV: fluorouracil (5FU) and leucovorin

mFOLFIRINOX*: fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and oxaliplatin

Gemcitabine (Gemzar)

Locally Advanced/Unresectable and Metastatic Disease | First Line of Therapy (1st Line) | ECOG PS: 0-2

FOLFIRINOX: fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and oxaliplatin

Gemcitabine (Gemzar)

Gemcitabine (Gemzar) and nab-paclitaxel (Abraxane)

Locally Advanced/Unresectable and Metastatic Disease | Second Line of Therapy (2nd Line) | ECOG PS: 0-2

Gemcitabine (Gemzar)

*Modified FOLFIRINOX: Bolus 5-FU not administered

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.



8600 West Bryn Mawr Avenue
South Tower - Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 11/27/2018 | Effective date: 2/4/2019

Appropriate.Safe.Affordable
© 2019 AIM Specialty Health
9019-2019